CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Ortho-Cyclen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01458210
NCT01458210Phase 1Completed
CompareCT.gov

Effect of Dulaglutide (LY2189265) on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Eli Lilly and Company·interventional·Posted Oct 24, 2011·Updated Oct 8, 2014

In Brief

A Phase 1 clinical trial evaluating Ortho-Cyclen and Dulaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to look at how the body processes oral contraceptive (OC), using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy female participants, and the effect of dulaglutide on how Ortho-Cyclen is processed by the body. Information about any side effects that may occur will also be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 24, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.7 years ago

Interventions

Ortho-Cyclendrug

Administered orally

Dulaglutidebiological

Administered subcutaneously